

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Leuven, BELGIUM, Boston, MA, US – April 24, 2023 – 8.00 PM CET [Oxurion NV](#) (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received transparency notifications as follows:

Oxurion received a transparency notification on April 14, 2023, from Atlas Special Opportunities LLC indicating that as of March 23, 2023, it held 11,055,598 shares of the then outstanding 603,716,557 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 1.

Oxurion received a transparency notification on April 19, 2023, from Atlas Special Opportunities LLC indicating that as of March 30, 2023, it held 7,055,741 shares of the then outstanding 632,659,186 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 2.

Oxurion received a transparency notification on April 14, 2023, from Atlas Special Opportunities LLC indicating that as of April 12, 2023, it held 15,407,185 shares of the then outstanding 659,387,625 shares, and therefore crossed below the threshold (3%) by virtue of sale of voting securities. See Annex 3.

In addition, on April 14, 2021, Oxurion announced the receipt on April 12, 2023, of a transparency notification from Atlas Special Opportunities LLC indicating that as of April 11, 2023, Atlas held 26,728,439 shares of the then outstanding 632,659,186 shares and therefore had crossed above the threshold (3%) by virtue of the acquisition of voting securities. The correct transaction date for this notice was however April 5, 2023. See Annex 4.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any

forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10</p> <p>" tom.graney@oxurion.com</p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway mtconway@conwaycommsir.com</p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com</p>
---	---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Downward crossing of the lowest threshold
Acquisition or disposal of voting securities or voting rights

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

23/03/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 22/03/2023, Atlas Special Opportunities LLC acquired 19,013,817 shares in Oxurion NV.

Done at New York

On 11/04/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature DocuSign by:
Patrick Vance
0334027820544C

ANNEX 2

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Downward crossing of the lowest threshold
Acquisition or disposal of voting securities or voting rights

4) Notification by

A person that notifies alone

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

30/03/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

632,659,186

Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights	# of voting rights	Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	11,055,598	7,055,741	0	1.12%	0.00%
TOTAL		7,055,741		1.12%	

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone". For groups, start with the ultimate controlling natural person or legal entity. The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.



uSign Envelope ID: E351CCC3-143D-4DA4-902E-6FDE34E11348

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL						

The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	7,055,741	1.12%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

On 28/03/2023, Atlas Special Opportunities LLC acquired 28,942,629 shares in Oxurton NV.

Done at New York

On 12/04/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature DocuSigned by:
Patrick Vance
5534B237B29544C...

ANNEX 3

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

12/04/2023 (DD/MM/YYYY)


8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

659,387,625

 Please enter the denominator before filling in the data


10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	26,728,439	15,407,185	0	2.34%	0.00%
TOTAL		15,407,185		2.34%	

 Start with "groups" of holders. Add subtotals with Σ and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

cuSign Envelope ID: 5C26C860-4988-49C9-8F84-2A5350A142D0

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL						

 The totals will be updated once you have clicked on **<CALCULATE>**

TOTAL (A & B)	CALCULATE	# of voting rights 15,407,185	% of voting rights 2.34%
---------------	------------------	----------------------------------	-----------------------------

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information


Done at New York

On 13/04/2023 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature DocuSigned by:
Patrick Vance
55348237B2854C...

ANNEX 4

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

+

4) Notification by

A person that notifies alone

+

5) Persons subject to the notification requirement


Name	Address (for legal entities)
Atlas Special Opportunities LLC	2500 Westchester Avenue, Suite 401, Purchase, NY 10577

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

05/04/2023 (DD/MM/YYYY)


8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10


9) Denominator

632,659,186


 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities LLC	7,055,741	26,728,439	0	4.22%	0.00%
TOTAL		26,728,439	0	4.22%	0.00%

 Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on **<CALCULATE>**.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on **<CALCULATE>**

TOTAL (A & B)		# of voting rights	% of voting rights
	CALCULATE	26,728,439	4.22%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Atlas Special Opportunities LLC is not a controlled entity.

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

Done at New York

On 11/04/2024 (DD/MM/YYYY)

Name & capacity Patrick Vance, proxyholder

Signature DocuSigned by:
Patrick Vance
65948237829644C